[1] Torti SV, Torti FM. Iron and cancer:more ore to be mined[J]. Nat Rev Cancer, 2013, 13(5):342-355.
[2] Lamy PJ, Durigova A, Jacot W. Iron homeostasis and anemia markers in early breast cancer[J]. Clin Chim Acta, 2014, 434:34-40.
[3] Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango:regulation of mammalian iron metabolism[J]. Cell, 2010, 142(1):24-38.
[4] Zhang F, Wang W, Tsuji Y, et al. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest[J]. J Biol Chem, 2008, 283(49):33911-33918.
[5] Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells[J]. Hepatology, 2009, 49(3):887-900.
[6] Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells[J]. Metallomics, 2014, 6(4):748-773.
[7] Lorenzi M, Lorenzi B, Vernillo R. Serum ferritin in colorectal cancer patients and its prognostic evaluation[J]. Int J Biol Markers, 2006, 21(4):235-241.
[8] Wang W, Knovich MA, Coffman LG, et al. Serum ferritin:Past, present and future[J]. Biochim Biophys Acta, 2010, 1800(8):760-769.
[9] Ashourpour M, Djalali M, Djazayery A, et al. Relationship between serum ferritin and inflammatory biomarkers with insulin resistance in a Persian population with type 2 diabetes and healthy people[J]. Int J Food Sci Nutr, 2010, 61(3):316-323.
[10] Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Gonzalez ME, et al. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy[J]. Leuk Lymphoma, 2015, 56(11):3096-3102.
[11] Habashy HO, Powe DG, Staka CM, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen[J]. Breast Cancer Res Treat, 2010, 119(2):283-293.
[12] Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer[J]. Biochim Biophys Acta, 2012, 1820(3):291-317.
[13] Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines[J]. Blood Cells Mol Dis, 2007, 39(1):82-91.
[14] Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regulation in breast cancer progression and prognosis[J]. Sci Transl Med, 2010, 2(43):43-56.
[15] Qiao B, Sugianto P, Fung E, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination[J]. Cell Metab, 2012, 15(6):918-924.
[16] Nemeth E. Hepcidin biology and therapeutic applications[J]. Expert Rev Hematol, 2010, 3(2):153-155.
[17] Ganz T, Nemeth E. Iron metabolism:interactions with normal and disordered erythropoiesis[J]. Cold Spring Harb Perspect Med, 2012, 2(5):a011668.
[18] Pasricha SR, Frazer DM, Bowden DK, et al. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major:a longitudinal study[J]. Blood, 2013, 122(1):124-133.
[19] Chen G, Fillebeen C, Wang J, et al. Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts[J]. Carcinogenesis, 2007, 28(4):785-791.
[20] Maffettone C, Chen G, Drozdov I, et al. Tumorigenic properties of iron regulatory protein 2(IRP2) mediated by its specific 73-amino acids insert[J]. PLoS One, 2010, 5(4):e10163.
[21] Thierbach R, Schulz TJ, Isken F, et al. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice[J]. Hum Mol Genet, 2005, 14(24):3857-764.
[22] Thierbach R, Drewes G, Fusser M, et al. The Friedreich's ataxia protein frataxin modulates DNA base excision repair in prokaryotes and mammals[J]. Biochem J, 2010, 432(1):165-172.
[23] Sun Y, Yokoi K, Li H, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models[J]. Clin Cancer Res, 2011, 17(13):4331-4340.
[24] Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification[J]. Cancer Epidemiol, 2012, 36(5):e294-e299.
[25] Keith B, Johnson RS, Simon MC. HIF1 alpha and HIF2 alpha:sibling rivalry in hypoxic tumour growth and progression[J]. Nat Rev Cancer, 2012, 12(1):9-22.
[26] Lau AT, Wang Y, Chiu JF. Reactive oxygen species:current knowledge and applications in cancer research and therapeutic[J]. J Cell Biochem, 2008, 104(2):657-667.
[27] Salganik RI. The benefits and hazards of antioxidants:controlling apoptosis and other protective mechanisms in cancer patients and the human population[J]. J Am Coll Nutr, 2001, 20(5 Suppl):464S-472S; discussion 473S-475S.
[28] Wang HC, Choudhary S. Reactive oxygen species-mediated therapeutic control of bladder cancer[J]. Nat Rev Urol, 2011, 8(11):608-616.
[29] Fang D, Bao Y, Li X, et al. Effects of iron deprivation on multidrug resistance of leukemic K562 cells[J]. Chemotherapy, 2010, 56(1):9-16.
[30] Liu X, Madhankumar AB, Slagle-Webb B, et al. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents[J]. Cancer Res, 2011, 71(6):2240-2249.
[31] Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma[J]. Gynecol Oncol, 2006, 100(1):116-127.
[32] Richardson DR, Kalinowski DS, Lau S, et al. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents[J]. Biochim Biophys Acta, 2009, 1790(7):702-717.
[33] Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer[J]. Crit Rev Oncol Hematol, 2002, 42(3):267-281.
[34] Kovacevic Z, Chikhani S, Lovejoy DB, et al. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1:a new strategy for the treatment of pancreatic cancer[J]. Mol Pharmacol, 2011, 80(4):598-609.
[35] Coombs GS, Schmitt AA, Canning CA, et al. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer[J]. Oncogene, 2012, 31(2):213-225.
[36] Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis:a useful target for cancer therapy[J]. J Membr Biol, 2014, 247(4):291-307.